ChironWells focuses on lead identification and preclinical development of therapeutic drug candidates  of the morphinan class. ChironWells is technology leader in medicinal chemistry of morphinans and disposes of a  broad portfolio of composition of matter patents. The proprietary technology platform has led to a highly  competitive development portfolio of small molecules in commercially attractive therapeutic areas.  ChironWells’ primary therapeutic areas are:    Pain management: ChironWells develops safer opioid analgesics with a greatly improved side effect profile  as new medications for the treatment of moderate-to-severe acute and chronic pain.    Immunological diseases: New treatments are targeted to offer therapeutic improvement for patients  suffering of atopic dermatitis, psoriasis and rheumatoid arthritis.     Gastrointestinal disorders: ChironWells offers innovative pharmacotherapies for inflammatory bowel  diseases (IBD) including Morbus Crohn and ulcerative colitis, and bowel motility disorders including  postoperative ileus (POI) and opioid-induced bowel dysfunction (OBD).   Legal Disclaimer